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Background: The prevalence of heart failure (HF) is rising in industrialized and developing countries. Though
invasive coronary angiography (ICA) remains the gold standard for anatomical assessment of coronary artery
disease in HF patients, alternatives are being sought. Computed tomographic coronary angiography (CTA) has
emerged as an accurate non-invasive diagnostic tool for coronary artery disease (CAD) and has been demonstrated
to have prognostic value. Whether or not CTA can be used in HF patients is unknown. Acknowledging the aging
population, the growing prevalence of HF and the increasing financial burden of healthcare, we need to identify
non-invasive diagnostic tests that are available, safe, accurate and cost-effective.
Methods/Design: The proposed study aims to provide insight into the efficacy of CTA in HF patients. A multicenter
randomized controlled trial will enroll 250 HF patients requiring coronary anatomical definition. Enrolled patients will
be randomized to either CTA or ICA (n = 125 per group) as the first test to define coronary anatomy. The primary
outcomes will be collected to determine downstream resource utilization. Secondary outcomes will include the
composite clinical events and major adverse cardiac events. In addition, the accuracy of CTA for detecting coronary
anatomy and obstruction will be assessed in patients who subsequently undergo both CTA and ICA. It is expected
that CTA will be a more cost-effective strategy for diagnosis: yielding similar outcomes with fewer procedural risks and
improved resource utilization.
Trial registration: ClinicalTrials.gov, NCT01283659
Team grant #CIF 99470Background
The prevalence of heart failure (HF) is on the rise in both
industrialized and developing countries [1-3]. Though the
diagnosis of HF often confers a poor prognosis, patient
outcomes vary widely according to the underlying etiology
of HF and subsequent therapy [2]. It has been long* Correspondence: bchow@ottawaheart.ca
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reproduction in any medium, provided the oraccepted that patients with ischemic cardiomyopathy and
significant viable myocardium may derive mortality benefit
from revascularization [2]. As such, invasive coronary
angiography (ICA) is often recommended in patients
with HF to define the presence or absence of coronary
artery disease (CAD) as the inciting etiology.
ICA remains the gold standard for the anatomical
assessment of coronary arteries and the diagnosis of
luminal stenoses. However, access to ICA in Canada
and other countries is limited, costly and has inherent
risks (death (0.12%), myocardial infarction (<0.05%),
stroke (0.1%) and bleeding (1.6%)), which prohibit itstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ICA would be desirable if it were available, accurate, safe,
and cost-effective.
Computed tomographic coronary angiography (CTA) has
emerged as an accurate non-invasive diagnostic tool for
CAD [4-8] and has been demonstrated to have prognostic
value [9-11]. Whether or not CTA can be used cost-
effectively in HF patients for diagnosis and to guide
patient investigations and management is unknown. This
is the focus of this randomized controlled trial (RCT).
To date, there are limited randomized controlled trials
(RCTs) that study the role of non-invasive imaging for
the diagnosis and management of patients with HF
[12]. To our knowledge, there are no RCTs examining
the utility of CTA in HF patients. Acknowledging the
aging population, the growing prevalence of HF and the
increasing financial burden of healthcare [1-3], we need to
identify non-invasive diagnostic tests that are cost-effective,
readily available and safe, and of sufficient accuracy to risk
stratify patients and guide investigations and management.
In 2007, the Canadian Institutes of Health Research
New Frontiers Program consensus conference identified
the need for comparative effectiveness research evaluation
of imaging, particularly in HF. In response, the IMAGE-
HF team project has been established The main goal of
IMAGE-HF is to evaluate cardiac imaging in HF. Studies
are divided into three broad levels: Level 1) research that
compares the effective use of existing clinical practice
strategies for HF to determine impact on relevant out-
comes; Level 2) research to evaluate emerging methods to
address specific HF populations; Level 3) research for the
development and evaluation of novel imaging biomarkers
in animal models of HF for potential translation to human
studies. Level 1 projects comprise three independent trials:
Project 1-A and 1-B are described separately [13,14].
The study herein is an IMAGE-HF Project 1-C called:
Computed Tomographic Coronary Angiography for Patients
with Heart Failure (CTA-HF): A Randomized Controlled
Trial. This study will compare the resource utilization
(downstream ICA, other testing and/or cardiac hospital-
ization) in terms of average health care costs per patient of
CTA compared to ICA in patients with progressive or
newly diagnosed HF (Figure 1).Objectives
The primary objective of this RCT is to compare the
average health care costs of CTA (experimental algorithm)
to ICA (standard of care) (Figure 1) as the initial test for
coronary anatomy in HF patients of unknown etiology.
The secondary objectives are to compare CTA versus
ICA for composite clinical events, major adverse
cardiac events (MACE), quality of life (QoL), radiation
exposure and safety.Hypotheses
The primary hypothesis is that, compared to ICA, a
diagnostic strategy algorithm using CTA for HF patients
will result in a reduction in downstream resource utilization
leading to a reduction in average costs per patient.
The first of two secondary hypotheses states that
compared to ICA (standard of care), a CTA strategy
will achieve: a) similar composite clinical events (CCE)
(cardiac death, myocardial infarction (MI), resuscitated
cardiac arrest and cardiac re-hospitalization (worsening
heart failure, acute coronary syndrome arrhythmia),
QoL, and MACE (cardiac death, non-fatal MI); b) a lower
rate of procedure related complications (death, MI, stroke,
vascular complications, severe allergic reactions; contrast
nephropathy); and c) a lower rate of normal ICA. The
second of the two secondary hypotheses states that using
patient-based analysis and vessel-based analysis, CTA has
very good agreement with ICA among patients with HF
in the CTA arm who proceed to ICA.Methods/Design
Design
CTA-HF is a multicenter, multinational, randomized con-
trolled trial that is currently recruiting 250 patients from
15 sites across Canada and Finland (see Additional file 1)
over 4 years, randomized to CTA versus ICA (n = 125
per group) as the first test to define coronary anatomy
in patients with heart failure. This research study has
approval from each participating center’s institutional
research ethics board.Eligibility criteria
All HF patients requiring investigation to determine the
etiology of HF (ischemic versus non-ischemic) will be
screened for the study. Eligible patients will have a docu-
mented history of left ventricular dysfunction (LVEF <50%
by radionuclide angiography (RNA), echocardiography or
magnetic resonance imaging (MRI)), or New York Heart
Association (NYHA) Class II to IV symptoms, or an
admission to hospital or emergency room for heart
failure within the past 12 months. As well, the HF patient
requires diagnostic information on coronary anatomy
because the diagnosis of CAD is uncertain or the definition
of coronary anatomy is required for management.
Patients will be excluded if they have: age <18 years,
lack of consent, renal insufficiency (glomerular filtration
rate, GFR <45 ml/min), allergy to intravenous contrast
agents, contraindications to radiation exposure (for example,
pregnancy), uncontrolled heart rate (HR, as per local clin-
ical routine), history of revascularization, atrial fibrillation,
frequent atrial or ventricular ectopy (>1/minute), inability
to perform 20-second breath-hold, and CTA or ICA within
the preceding 12 months.
Figure 1 IMAGE-HF Project I-C: experimental algorithm to evaluate use of tomographic coronary angiography (CTA) in determination
of heart failure (HF) etiology. Figure 1 illustrates the experimental model of this study, in which the ability of CTA to determine etiology of HF
will be compared to that of invasive coronary angiography (ICA). All patients exhibiting HF of unknown etiology will be considered; patients with
contraindications to CTA will be excluded.
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Randomization will be coordinated by the University of
Ottawa Heart Institute (UOHI) Cardiovascular Research
Methods Centre. Eligible, consenting patients will be
randomized to either the CTA or ICA arm and stratified
according to recruitment site. A stratified block (varying
sizes) randomization scheme will be used. Within each
stratum, patients will be randomized with varying block
sizes into the two study groups. A central randomization
scheme, ensuring concealment, will be used and the
site coordinator will perform patient assignments. The
randomization scheme will be generated by the study
statistician using a SAS (SAS Institute, Cary, North
Carolina, USA) macro.Data collection
All data will be collected using the Autonomy Process
Automation (AMA) formally called Liquid Office™, which
is a web-based solution for creating, routing, data cap-
turing and managing electronic forms. This will be done
in conjunction with the UOHI Cardiovascular Research
and Methods Centre and will be audited using standard
procedures.
Recruiting centers will be responsible for patient screen-
ing and local enrollment. Identification of patients will be
coordinated by physicians and support staff responsible
for scheduling coronary angiography. Local research staff
(under direction from the site principal investigator) will
identify and recruit patients for the study as well as be
responsible for the day-to-day management of the study.
A supervising research coordinator, based at the UOHI,
will oversee the multicenter study at all sites and routine
site visits will be made.
Interventions
Patients will be randomized to CTA (experimental algo-
rithm) versus ICA (standard of care).
Computed tomographic coronary angiography
Non-contrast enhanced prospective ECG-triggered image
acquisition will be acquired and the Agatston score will
be calculated [15]. Standard procedures will be applied
for contrast infusion, timing and image acquisition. As
per local clinical practice, prospective ECG-triggered or
retrospective ECG-gated data sets will be acquired using
bi- or tri-phasic contrast protocols. Vendor-specific radi-
ation dose-reducing techniques such as prospective ECG-
triggered image acquisition will be encouraged. A 4-point
grading score [normal, mild (<50%), moderate (50 to
69%), severe (≥70%)] will be used for the evaluation of
coronary stenosis using a 17-segment model. Similar to
ICA, obstructive CAD is defined as coronary diameter
stenosis ≥50% (Additional file 2).Invasive coronary angiography
ICA will be performed according to standard clinical
protocols, with selective coronary injection and images
acquired from multiple oblique views (Additional file 2).
Patients with obstructive CAD will be categorized as
having high risk CAD (defined as having a left main
stenosis (≥50%), or three-vessel disease (VD) (≥70%) or
two-VD (≥70%) involving the proximal left anterior
descending artery) or non-high risk CAD [9].
Following either CTA or ICA, information on the results
will be disseminated to the referring physician as part of
their standard clinical care.
Outcome measures
The primary outcome (average health care costs per
patient) will be determined through regression methods
detailed below.
All secondary outcome measures will be determined:
(CCE (cardiac death, myocardial infarction, resuscitated
cardiac arrest and cardiac re-hospitalization (worsening
heart failure, acute coronary syndrome arrhythmia), QoL,
procedural complications (all-cause death, myocardial in-
farction, stroke, vascular complications, severe allergic reac-
tions; contrast nephropathy), and rate of normal ICA.
CTA accuracy: To address the 2nd secondary hypothesis,
regarding CTA accuracy, the accuracy in the cohort of
patients randomized to CTA and undergoing subsequent
ICA (sensitivity, specificity, predictive values and likelihood
ratios) will be determined and reported with 95% confi-
dence intervals (CI). It is estimated that 50/125 of the pa-
tients randomized to CTA will have subsequent ICA,
which will enable the comparison of CTA accuracy to ICA.
Frequency and duration of follow-up
Telephone follow-up will be performed at 3, 6 and 12
months, and every 12 months thereafter. Follow-up will
continue until the termination of the trial (mean = 3 years;
range 2 to 4 years) (Figure 2).
Safety and ethics
The study protocol will be approved by each institution’s
research ethics board and informed consent form will
be obtained from enrolled patients. This study will be
conducted according to the Declaration of Helsinki, Good
Clinical Practice and the TriCouncil Policy.
Sample size
Typically, sample sizes for economic analyses are based
upon practical and logistic reasons with limited focus on
inferential statistics [16]. Within this study, incremental
costs will be estimated through regression analysis, which
will incorporate a significant number of covariates to
adjust for the nonrandom nature of treatment allocation.
Based on traditional sample size calculations for regression
Figure 2 Timeline for IMAGE-HF Project I-C patient follow-up.
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for a large number of coefficients (at least 25) and give a
suitable degree of precision around our primary outcome
[17]. For example, if the coefficient of variation for costs
was 25%, there would be sufficient power to detect a
reduction in costs by 10%.
Data analysis
For the purposes of data analysis, two study groups will
be defined: ‘intention-to-treat’ (ITT) population which
consists of all patients who are randomized to the CTA
or ICA regardless of whether they actually receive the
approach, and ‘per protocol’ population which excludes
patients randomized but not receiving the allocated
approach. Primary analyses will be conducted on the
ITT population, and the sensitivity analyses will be
conducted on the per-protocol population. Descriptive
statistics for the baseline demographic characteristics
will be summarized for the study group by means of
frequency for categorical variables and mean, standard
deviation, median and interquartile ranges for con-
tinuous variables. Demographic information includes
age, comorbidities, cardiac history, cardiac risk factors and
medications. Groups will be compared on continuous
variables using Wilcoxon rank-sum tests and on cat-
egorical variables using Fisher’s exact tests.
Primary analysis
Primary analysis will estimate average health care costs
per patient for CTA versus ICA. Resource utilization will
be measured as detailed below. Cost is defined as the
incremental cost of the diagnostic strategy using CTA
and will represent the primary outcome measure. Cost
will be estimated through regression methods detailed
below. Thus, estimations of incremental cost will be
evaluated based on costing the components of care.
Secondary analysis
Secondary analysis will investigate CCE and MACE, an-
alyzed using survival analysis techniques between the
ICA and CTA arms. The survival experience (that is,
time-to-major adverse cardiac event) in each of the two
arms will be summarized using Kaplan-Meier productlimit estimates and the log-rank test will be used for
comparing the survival curves. The hazard ratio with
95% confidence interval (CI) will be calculated. To adjust
for possible effects of covariates on survival, the Cox’s
proportional hazards model will be used. Underlying
assumptions for these statistical procedures will be
assessed; in particular, the proportional hazard assump-
tion will be assessed using graphical and numerical
tests, and stratified Cox models or Aalen’s additive model
will be considered as needed.Safety
The proportion of various procedural complications will
be compared descriptively using chi-square tests to deter-
mine relative safety of CTA to ICA. Patient morbidity/
health-related QOL associated with CTA and/or ICA will
be compared using Student-t tests for the overall scores
and utility.
The accuracy (operating characteristics) of CTA in
the identification of high-risk coronary anatomy and
obstructive CAD (per-patient/vessel/segment analysis)
will be assessed in the cohort of patients undergoing
both CTA and ICA. A receiver operating characteristic
(ROC) curve analysis will be conducted for the vessel
disease number, and the weighted kappa with 95% CI
will be calculated to assess the agreement between
CTA and ICA for the allocation of patients into the
groups: 0-, 1-, 2- or 3-vessel disease; high-risk CAD;
and non-high risk CAD. ROC analysis will also be per-
formed on a per-patient, per-vessel and per-segment
basis. In the patients who undergo both CTA and ICA,
the accuracy of CTA to predict subsequent early revas-
cularization will be assessed as follows: the point esti-
mates with 95% CI for the sensitivity (Se), specificity
(Sp), positive predictive value (PPV), and negative
predictive value (NPV) of CTA in identifying a
patient for revascularization (medical therapy (no
obstructive CAD) versus revascularization (PCI (non-
high risk CAD) versus CABG (high-risk CAD)) using
ICA as the gold standard will be calculated. They
will be adjusted for referral bias using the Diamond
method [18].
Chow et al. Trials 2013, 14:443 Page 6 of 8
http://www.trialsjournal.com/content/14/1/443Cost analysis
Analysis will take the form of a simple cost minimization
analysis comparing a management algorithm using CTA
versus ICA. Analysis will be restricted to the follow-up
period within the study database and will be conducted
from the health care system perspective.
Costs
Costs can be grouped into four main categories: initial
imaging modalities, medications, hospitalizations and on-
going patient management. The total costs for each patient
will be estimated through a simple two-stage process;
measurement and valuation of resource use. Following
this, the incremental costs associated with the use of
CTA will be derived through regression modelling.
Measurement of physical quantities of resources consumed
As part of the database constructed for this project, data
on the use of health care resources are recorded. Specific
resources for which information will be collected are initial
imaging modalities, specialist outpatient appointments,
family physician consultations, medications, further testing
and investigations including invasive coronary angiography
and hospitalizations.
Valuation of resource use
For all resource items listed above an appropriate unit cost
will be derived. Unit costs will be obtained from appropri-
ate provincial fee schedules and administrative data as for
project 1A.
Costs associated with the use of computed tomographic
coronary angiography
The incremental cost associated with the management
algorithm that includes the use of CTA will be estimated
as follows. A data set will be constructed containing the
total costs per patient. For each observation the patient
will be assigned a dummy variable relating to whether they
were assigned to the management algorithm or to stand-
ard care. Regression will be conducted using appropriate
generalized linear models controlling for all potential
covariates. The appropriate coefficient from the regression
will represent the incremental cost associated with the use
of CTA.
Analysis of uncertainty
Given the complex nature of cost data, generalized linear
models (GLMs) will be adopted to determine the incre-
mental costs associated with CTA. GLMs are attractive in
the analysis of cost data as these models involve a para-
metric method where non-normal distributions can be
specified and the way the dependent variable and the
independent variables interact can be altered [18]. GLMs
involve a link function that specifies the relationshipbetween the mean and the covariates and a family, which
specifies the assumed mean-variance relationship. Differ-
ent families and link functions are available. The modified
Parks test can be used to determine the appropriate family
while the novel technique of extended estimating equa-
tions has been developed, which allows identification of
both the link function and family [18-20]. The regression
model will provide 95% confidence intervals around
the estimate of incremental costs. Univariate sensitivity
analysis will be conducted to assess the robustness of
the study’s results to changing assumptions related to
the unit costs of specific resource items. In addition,
where available, sensitivity analysis will be conducted
utilizing resource use data.
Missing data
‘Missingness’ is considered to be missing at random (MAR)
and mixed methods repeated measures (MMRM) and mul-
tiple imputation (MI) techniques will be used for handling
missing data. In particular, for continuous outcomes at
multiple time points, MMRM will be used.
Study management
The IMAGE-HF trial is managed by an Executive Com-
mittee consisting of clinicians specialized in diagnostic
imaging and heart failure and experts in biostatistics,
physics and radiochemistry, as well as a larger Steering
Committee consisting of members of the Executive Com-
mittee and representatives of all the initial study centers.
In addition, an events adjudication committee (blinded to
patient allocation) will independently review and adjudi-
cate each clinical event. Since all the imaging approaches
are part of standard clinical practice, no interim analysis
is planned, but there will be independent data safety
monitoring board (DSMB), which will review the safety
data on a periodic basis.
Discussion
The proposed RCT is the largest RCT in HF patients to
compare CTA versus ICA. This RCT will accomplish
several goals: 1) it will determine feasibility and diagnostic
accuracy of CTA in patients with undifferentiated heart
failure; 2) if feasible, it will determine if the incorporation
of CTA into the investigation algorithm of HF patients is
cost-effective; and 3) it will determine if the CTA strategy,
compared to ICA, is safe.
If these hypotheses are supported, study findings will
have significant implications related to clinical practice.
Evidence that CTA is effective in distinguishing etiology
of HF at a lower cost with reductions in unnecessary ICA
testing, subsequently with fewer procedure-associated
complications, would be very attractive to clinicians and
patients. This may further contribute to a reduction in
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care systems worldwide.
Trial status
This randomized clinical trial is currently recruiting
subjects.
Additional files
Additional file 1: Table S1. List of IMAGE-HF participating sites and
investigators.
Additional file 2: Standardization and quality assurance.
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